myRocky vs NowPatient
NowPatient costs $340 less a month, and both sell semaglutide and tirzepatide.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
If you are choosing between myRocky and NowPatient, the first difference is cost: NowPatient is $340 a month cheaper at the entry price. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. NowPatient leads our six-part score, 6.1 to 5.6.
myRocky vs NowPatient price
NowPatient is the cheaper way in: $1,069 a month against $1,409 a month at myRocky. That is $340 less each month (24% lower), or about $4,080 over a year of treatment.
Drug by drug: Semaglutide is cheaper at NowPatient ($1,349 a month vs $1,409 a month); tirzepatide is cheaper at NowPatient ($1,069 a month vs $1,409 a month).
Medications and formats
Both sell semaglutide and tirzepatide; only NowPatient lists liraglutide.
On format they match: each offers brand-name pens.
Where each one treats patients
Neither myRocky nor NowPatient publishes the states it serves, so enter your state at the very start of each sign-up.
Pricing
myRocky
NowPatient
What each price covers
NowPatient's price also covers the clinician visit and the medication itself, which myRocky does not claim.
myRocky does not say what its price includes.
NowPatient is silent on shipping, lab work and coaching.
That matters most for the drug: unless myRocky confirms otherwise, budget for medication on top of its listed price.
myRocky
Inclusions not disclosed.
NowPatient
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
Where each one scores higher
Overall, NowPatient scores 6.1 and myRocky 5.6 out of 10.
myRocky is stronger on user experience (3.0 vs 2.5).
NowPatient is stronger on value (6.1 vs 4.1) and support (5.5 vs 5.0).
Effectiveness, trust & safety and accessibility are within half a point.
myRocky
5.6/10
NowPatient
6.1/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
Neither myRocky nor NowPatient has an FDA warning letter on record with us.
Features & Coverage
| Feature | myRocky | NowPatient |
|---|---|---|
| Starting Price | $1,409/mo | ✓$1,069/mo |
| Features | ✓8 features | 2 features |
| States Available | Not disclosed | Not disclosed |
| Compounded | — | — |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | None | None |
About myRocky
The fees pile up: $99 to consult at the start, then $99/month as a program fee, and the medication on top of that, with Ozempic shown at roughly $1,409/month. Rocky Health Inc. is incorporated in Ontario, Canada and sells brand-name drugs, Ozempic, Mounjaro and Wegovy, into the US market; nothing compounded is offered. The same subscription also reaches sexual health, hair loss and mental health.
Read our full myRocky review →About NowPatient
Nothing is charged for the consultation at NowPatient; the medication is the whole bill. Because the out-of-pocket cost tracks brand list prices, an uninsured patient faces roughly $1,000-$1,350/mo. Access is to brand-name GLP-1s for weight management: Saxenda is on the menu, so is Mounjaro, and Wegovy comes as an injection and as an oral tablet. The company spans the US and UK, HQ Austin, TX.
Read our full NowPatient review →Pros & Cons
myRocky
What we like
- Tirzepatide costs $1409 a month, close to the $1249 median for brand-name tirzepatide across the sellers we compare
- We found no FDA warning letters issued to myRocky
Watch-outs
- Semaglutide costs $1409 a month, 41% above the $997 median for brand-name semaglutide across the sellers we compare
- You only see a price after finishing the medical intake, so you cannot compare costs before sharing health information
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
NowPatient
What we like
- Tirzepatide costs $1069 a month, 14% below the $1249 median for brand-name tirzepatide across the sellers we compare
- The monthly price includes the medication and clinician visits
- We found no FDA warning letters issued to NowPatient
- A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
Watch-outs
- Semaglutide costs $1349 a month, 35% above the $997 median for brand-name semaglutide across the sellers we compare
- You only see a price after finishing the medical intake, so you cannot compare costs before sharing health information
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
Our Verdict
NowPatient wins this one, 6.1 to 5.6, above all for an oral route if you will not self-inject. It also costs $340 less each month than myRocky. myRocky fits better if a GLP-1 from $1409/month is your priority.
Choose myRocky if…
You want a GLP-1 from $1409/month and an opening price near $1,409 a month.
Choose NowPatient if…
You want an oral route if you will not self-inject and an opening price near $1,069 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
RxSpan MD
Knowing which pharmacy fills the vial: it names Belmar Pharmacy
From $249/mo
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $249/mo
Get started →Strut Health
Semaglutide at $99/month, 48% below the typical price
From $99/mo
Get started →myRocky vs NowPatient: FAQ
Close alternatives to myRocky and NowPatient
- myRocky vs Form Health
- myRocky vs Levity
- myRocky vs TrimRx
- myRocky vs Klinic
- NowPatient vs Alloy
- NowPatient vs Levity
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.